Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.59 |
| ▸ | MGLL | Q99685 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690679 | 0.80 | MGLL (0.68) | LMNANCEH1MGLL | |
| SCHEMBL19712947 | 0.71 | NCEH1 (0.48) | LMNASMN1; SMN2NCEH1RXFP1 | |
| SCHEMBL9657637 | 0.71 | NCEH1 (0.55) | NCEH1MGLL | |
| SCHEMBL20484104 | 0.70 | NCEH1 (0.43) | LMNASMN1; SMN2NCEH1MGLLRXFP1 | |
| SCHEMBL4600522 | 0.70 | MGLL (0.62) | MGLL | |
| SCHEMBL9658031 | 0.70 | NCEH1 (0.54) | NCEH1 | |
| SCHEMBL9657721 | 0.70 | MGLL (0.47) | MGLL | |
| SCHEMBL9660367 | 0.69 | NCEH1 (0.53) | NCEH1MGLL | |
| SCHEMBL9656968 | 0.69 | NCEH1 (0.53) | NCEH1 | |
| SCHEMBL9659092 | 0.68 | NCEH1 (0.52) | NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1558591-A4 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | UNIV CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1558591-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | The Regents of the University of California (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| WO-2004033422-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | LMNA 1522/4885SMN1; SMN2 4013/4885NCEH1 13/4885 |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | LMNA 1697/4885SMN1; SMN2 4010/4885NCEH1 15/4885 |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | LMNA 1752/4885SMN1; SMN2 3832/4885NCEH1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.